Omeros Corporation (NASDAQ:OMER) Q4 2024 Earnings Call Transcript
Q4 2024 Earnings Call Transcript March 31, 2025 Omeros Corporation beats earnings expectations. Reported EPS is $-0.54, ...
MPR3d
Fabhalta Approved as First Treatment for C3 Glomerulopathy
The approval of iptacopan in reducing proteinuria in adult patients with native kidney C3G was based on data from the randomized, double-blind, placebo-controlled, phase 3 APPEAR-C3G trial.
11 Best Gene Therapy Stocks to Buy According to Analysts
Here is our list of the 11 Best Gene Therapy Stocks to Buy According to Analysts.
Healio5d
Latest data show progress of GA therapies in the pipeline
The current state of treatment for geographic atrophy is marked by two approved therapies that slow GA progression: ...
Novartis13d
Novartis receives third FDA approval for oral Fabhalta® (iptacopan) – the first and only treatment approved in C3 glomerulopathy (C3G)
Basel, March 20, 2025 – Novartis today announced that oral Fabhalta ® (iptacopan) has received U.S. Food and Drug Administration (FDA) approval for the treatment of adults with C3 glomerulopathy (C3G) ...